Notice of Extra General Meeting in Biovica International AB

October 23, 2023 2:30 AM

UPPSALA, SWEDEN / ACCESSWIRE / October 23, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the extra general meeting to be held on Thursday 23 November 2023, at 14:00 CET at Baker McKenzie Advokatbyrå's offices on Vasagatan 7 in Stockholm.Right to attend the general meeting Shareholders wishing to attend the extra general...

Read more

Moolec Science Presents Fourth Quarter FY 2023 Business Update

October 20, 2023 5:00 PM

LUXEMBOURG / ACCESSWIRE / October 20, 2023 / Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, today reported its Business Update for the fourth quarter of Fiscal Year 2023 ended June 30, 2023. The main highlights of the Company's business update are as follows:Piggy Sooy™: introducing a soybean platform that can produce high amounts of pork...

Read more

Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris

October 20, 2023 10:00 AM

PARIS, FRANCE / ACCESSWIRE / October 20, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on Euronext in Paris ("Euronext Paris") as from 4:20 p.m....

Read more

Abivax Announces the Pricing of its Initial Public Offering on the Nasdaq Global Market 

October 20, 2023 9:15 AM

PARIS, FRANCE / ACCESSWIRE / October 20, 2023 / Abivax SA (Euronext Paris:FR0012333284:ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today the pricing of its initial public offering on the Nasdaq Global Market by way of a capital increase...

Read more

Abivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris

October 20, 2023 3:00 AM

PARIS, FRANCE / ACCESSWIRE / October 20, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today that trading of its ordinary shares on the regulated market of Euronext in Paris ("Euronext Paris")...

Read more

Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA

October 19, 2023 9:00 AM

Important step towards STENDRA potentially becoming the first erectile dysfunction medication to successfully achieve OTC StatusNEW YORK, NY / ACCESSWIRE / October 19, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs, announces initiation of a self-selection study using the Drug Facts Label (DFL) tested during its previously...

Read more

Abivax Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Price Range

October 18, 2023 6:17 PM

PARIS, FRANCE / ACCESSWIRE / October 18, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced the formal commencement of book-building and the filing of an amended registration statement on Form...

Read more

BiotechTuesday to Host Halloween Edition Event at SmartLabs’ Newest Boston Area Location

October 18, 2023 1:15 PM

BOSTON, MA / ACCESSWIRE / October 18, 2023 / SmartLabs, which accelerates science through a portfolio of cutting-edge services for laboratory design, operations, and infrastructure, invites the biotech, biopharma, and life sciences community of Greater Boston to attend a BiotechTuesday event at its newest advanced managed research center in Cambridge. 100 Cambridgeside Place in East Cambridge is a premier mixed-use space featuring shops and...

Read more

Celcuity Inc. Announces $50 Million Private Placement

October 18, 2023 9:15 AM

MINNEAPOLIS, MN / ACCESSWIRE / October 18, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, announced today that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $50 million. In the private placement, an institutional investor has agreed to purchase...

Read more

Moolec Science to Host Fiscal Year 2023 Business Update Conference Call

October 17, 2023 5:00 PM

LUXEMBOURG / ACCESSWIRE / October 17, 2023 / Moolec Science SA (NASDAQ:MLEC); ("Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, announced today that it will release its Business Update for the Fiscal Year 2023 on Friday, October 20, 2023, after the market closes. Moolec's Chief Executive Officer Gastón Paladini, Chief Financial Officer José López Lecube,...

Read more

Moolec Science Announces Capital Raise With Strategic Investors for ~US $30 Million

October 17, 2023 8:00 AM

LUXEMBOURG / ACCESSWIRE / October 17, 2023 // Moolec Science SA (NASDAQ: MLEC; "Company"; "Moolec''), a science-based food ingredient company, announced today that it has entered into agreements to issue a convertible note due 2026 to Grupo Insud ("Insud") in a principal amount of approximately US $21 million (the "Insud Convertible Note") with a strike price of US $6.00 per share. The Insud Convertible Note will be issued against a cash payment...

Read more

Moolec Science Announces ~US $30 Million Capital Raise With Strategic Investors

October 17, 2023 8:00 AM

LUXEMBOURG / ACCESSWIRE / October 17, 2023 // Moolec Science SA (NASDAQ:MLEC; "Company"; "Moolec''), a science-based food ingredient company, announced today that it has entered into agreements to issue a convertible note due 2026 to Grupo Insud ("Insud") in a principal amount of approximately US $21 million (the "Insud Convertible Note") with a strike price of US $6.00 per share. The Insud Convertible Note will be issued against a cash payment...

Read more

Abivax Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq Listing

October 16, 2023 12:00 PM

PARIS, FRANCE / ACCESSWIRE / October 16, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced the start of its roadshow in connection with its intention to issue, subject to market and other...

Read more

Tanvex CDMO Launch Empowers Advancements in Novel Biologics and Biosimilars

October 16, 2023 8:00 AM

New biologics outsourcing solution provider leverages proven track record of Tanvex BioPharma USA Inc. to help early-stage companies bring mammalian and microbial derived biologics from concept to commercialization.SAN DIEGO, CA / ACCESSWIRE / October 16, 2023 / Tanvex BioPharma USA Inc., a developer and manufacturer of biopharmaceuticals, has launched Tanvex CDMO to provide comprehensive biologic contract development and manufacturing services,...

Read more

Biovica Receives CAP Accreditation for its CLIA Laboratory

October 16, 2023 2:50 AM

UPPSALA, SWEDEN / ACCESSWIRE / October 16, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica today announces that it has received Laboratory Accreditation from the College of American Pathologists (CAP) for its Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in San Diego, California. CAP accreditation is awarded to laboratories that meet stringent requirements and maintain the highest standards for...

Read more

Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn

October 13, 2023 9:05 AM

Global exclusivity for all non-pharmaceutical applications of DehydraTECH-sulforaphane has been awardedMinimum ongoing payments, royalties and manufacturing revenues part of the agreementKELOWNA, BC / ACCESSWIRE / October 13, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has granted a new global, exclusive license to use DehydraTECH technology...

Read more

Ondine Biomedical Inc. - Steriwave now in Canada's East Coast

October 13, 2023 2:00 AM

Nova Scotia's largest hospital is the latest to implement Steriwave nasal photodisinfection for use prior to orthopedic surgeryVANCOUVER, BC / ACCESSWIRE / October 13, 2023 / Canadian life sciences company Ondine Biomedical's (LSE:OBI) Steriwave® nasal photodisinfection for the prevention of healthcare-associated infections (HAIs) is now available in hospitals across Canada. The latest hospital to implement Steriwave for its orthopedic surgery...

Read more

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

October 12, 2023 12:15 PM

Revolving Line of Credit to Support Completion of Government-Funded ARDS StudyTORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa", or the "Company"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced it has entered into a binding commitment letter in respect of a $10 million revolving credit facility agreement with Dr. Par Nijhawan, MD, the...

Read more

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

October 12, 2023 12:10 PM

TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitment of up to C$23 million from the Government of Canada for a pivotal Phase 3 clinical study of the company's first-in-class therapeutic candidate.Edesa's experimental drug, called EB05 (paridiprubart), represents a new class of emerging therapies...

Read more

Bionoid Pharma Signs Exclusive License Agreement with Global Alerts Corp.

October 12, 2023 10:15 AM

Landmark Deal Signed in Global Mass Notification Market:Exclusive License Agreement for Rapid Deployment of World-Leading Early Warning TechnologyTORONTO, ON / ACCESSWIRE / October 12, 2023 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce an exclusive license agreement with Global Alerts Corp. ("Global Alerts"), a distinguished technology company dedicated to the development and worldwide deployment of state-of-the-art...

Read more